CU24763B1 - Proteínas de fusión compuestas por un anticuerpo y una muteína agonista de interleucina 2 - Google Patents

Proteínas de fusión compuestas por un anticuerpo y una muteína agonista de interleucina 2

Info

Publication number
CU24763B1
CU24763B1 CU2021000104A CU20210104A CU24763B1 CU 24763 B1 CU24763 B1 CU 24763B1 CU 2021000104 A CU2021000104 A CU 2021000104A CU 20210104 A CU20210104 A CU 20210104A CU 24763 B1 CU24763 B1 CU 24763B1
Authority
CU
Cuba
Prior art keywords
mutein
fusion proteins
interleukin
agonist
antibody
Prior art date
Application number
CU2021000104A
Other languages
English (en)
Other versions
CU20210104A7 (es
Inventor
Pazos Ana Victoria Casadesús
García Tays Hernández
Monzón Kalet León
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Priority to CU2021000104A priority Critical patent/CU24763B1/es
Priority to CA3241426A priority patent/CA3241426A1/en
Priority to US18/722,557 priority patent/US20250049890A1/en
Priority to PCT/CU2022/050012 priority patent/WO2023116951A1/es
Priority to AU2022420223A priority patent/AU2022420223A1/en
Priority to MX2024007683A priority patent/MX2024007683A/es
Priority to EP22850571.5A priority patent/EP4455162A1/en
Priority to KR1020247023731A priority patent/KR20240123829A/ko
Priority to CN202280085138.9A priority patent/CN118434770A/zh
Priority to JP2024537810A priority patent/JP2024547098A/ja
Publication of CU20210104A7 publication Critical patent/CU20210104A7/es
Priority to CONC2024/0009333A priority patent/CO2024009333A2/es
Priority to ZA2024/05597A priority patent/ZA202405597B/en
Publication of CU24763B1 publication Critical patent/CU24763B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001124—CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>La presente invención se relaciona con el campo de la Biotecnología y la Inmuno-oncología. Se describen proteínas de fusión que comprenden una muteína agonista de interleucina 2 unida a una inmunoglobulina por medio de un enlazador. Estas proteínas de fusión son útiles en el tratamiento del cáncer dadas sus propiedades superiores a otras similares basadas en muteína IL-2 no alfa, al conservar simultáneamente la capacidad de los anticuerpos de hacer ADCC y CDC y, además activar células NK y TCD8<sup>+</sup>, sin expandir células T reguladoras. La convergencia de estas propiedades resulta en proteínas de fusión con propiedades antitumorales superiores a los anticuerpos parentales, e incluso, a la combinación de estos con la muteína no alfa.</p>
CU2021000104A 2021-12-21 2021-12-21 Proteínas de fusión compuestas por un anticuerpo y una muteína agonista de interleucina 2 CU24763B1 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CU2021000104A CU24763B1 (es) 2021-12-21 2021-12-21 Proteínas de fusión compuestas por un anticuerpo y una muteína agonista de interleucina 2
MX2024007683A MX2024007683A (es) 2021-12-21 2022-12-09 Proteinas de fusion compuestas por un anticuerpo y una muteina.
US18/722,557 US20250049890A1 (en) 2021-12-21 2022-12-09 Fusion proteins composed of an antibody and a mutein
PCT/CU2022/050012 WO2023116951A1 (es) 2021-12-21 2022-12-09 Proteínas de fusión compuestas por un anticuerpo y una muteina
AU2022420223A AU2022420223A1 (en) 2021-12-21 2022-12-09 Fusion proteins composed of an antibody and a mutein
CA3241426A CA3241426A1 (en) 2021-12-21 2022-12-09 Fusion proteins composed of an antibody and a mutein
EP22850571.5A EP4455162A1 (en) 2021-12-21 2022-12-09 Fusion proteins composed of an antibody and a mutein
KR1020247023731A KR20240123829A (ko) 2021-12-21 2022-12-09 항체 및 뮤테인으로 구성된 융합 단백질
CN202280085138.9A CN118434770A (zh) 2021-12-21 2022-12-09 由抗体和突变蛋白组成的融合蛋白
JP2024537810A JP2024547098A (ja) 2021-12-21 2022-12-09 抗体とムテインとからなる融合タンパク質
CONC2024/0009333A CO2024009333A2 (es) 2021-12-21 2024-07-15 Proteínas de fusión compuestas por un anticuerpo y una muteina
ZA2024/05597A ZA202405597B (en) 2021-12-21 2024-07-18 Fusion proteins composed of an antibody and a mutein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2021000104A CU24763B1 (es) 2021-12-21 2021-12-21 Proteínas de fusión compuestas por un anticuerpo y una muteína agonista de interleucina 2

Publications (2)

Publication Number Publication Date
CU20210104A7 CU20210104A7 (es) 2023-07-12
CU24763B1 true CU24763B1 (es) 2025-07-09

Family

ID=85121950

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2021000104A CU24763B1 (es) 2021-12-21 2021-12-21 Proteínas de fusión compuestas por un anticuerpo y una muteína agonista de interleucina 2

Country Status (12)

Country Link
US (1) US20250049890A1 (es)
EP (1) EP4455162A1 (es)
JP (1) JP2024547098A (es)
KR (1) KR20240123829A (es)
CN (1) CN118434770A (es)
AU (1) AU2022420223A1 (es)
CA (1) CA3241426A1 (es)
CO (1) CO2024009333A2 (es)
CU (1) CU24763B1 (es)
MX (1) MX2024007683A (es)
WO (1) WO2023116951A1 (es)
ZA (1) ZA202405597B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
CU22731A1 (es) 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
WO2008036688A2 (en) * 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
CU23923B1 (es) * 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
US9266938B2 (en) 2011-02-10 2016-02-23 Roche Glycart Ag Mutant interleukin-2 polypeptides
CU24483B1 (es) 2016-11-15 2020-04-02 Ct Inmunologia Molecular Método para incrementar los niveles de secreción de la interleucina-2

Also Published As

Publication number Publication date
CN118434770A (zh) 2024-08-02
ZA202405597B (en) 2025-04-30
WO2023116951A1 (es) 2023-06-29
US20250049890A1 (en) 2025-02-13
CU20210104A7 (es) 2023-07-12
CA3241426A1 (en) 2023-06-29
AU2022420223A1 (en) 2024-08-01
MX2024007683A (es) 2024-07-09
EP4455162A1 (en) 2024-10-30
JP2024547098A (ja) 2024-12-26
KR20240123829A (ko) 2024-08-14
CO2024009333A2 (es) 2024-08-08

Similar Documents

Publication Publication Date Title
CY1125347T1 (el) Ειδικοι σε κλαουδινη-18.2 ανοσοϋποδοχεις και επιτοποι τ-κυτταρων
PE20241349A1 (es) Anticuerpos de union a cd3
MX2022001321A (es) Anticuerpo biespecifico anti-ctla4/anti-pd-1 y uso del mismo.
CY1123534T1 (el) Αντισωματα που περιλαμβανουν τροποποιημενες βαριες σταθερες περιοχες
EA202092306A1 (ru) Анти-cd24 композиции и их применения
MX2020012286A (es) Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t.
MX392369B (es) Anticuerpos anti-ilt4 y fragmentos de union a antigeno.
ECSP19040905A (es) Anticuerpos anti-tim-3 para combinar con anticuerpos anti-pd-1
CL2017001866A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
MX2019002254A (es) Anticuerpo bifuncional anti-ctla4 y anti-pd-1, composicion farmaceutica y uso de este.
AR114284A1 (es) Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
BR112019008861A2 (pt) anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3)
PE20190737A1 (es) Anticuerpos anti-cd27
MX2021013586A (es) Anticuerpo monoclonal anti-antigeno 4 asociado a linfocitos t citotoxicos (ctla4) o su fragmento de union a antigeno, una composicion farmaceutica y uso.
NZ720520A (en) Tagged chimeric effector molecules and receptors thereof
CO2022009737A2 (es) Anticuerpos anti-ly6g6d y métodos de uso
MX2022001111A (es) Anticuerpo anti-pd-1 y uso farmaceutico del mismo.
PE20200927A1 (es) Anticuerpos monoclonales que se unen a la region de la cadena beta de la familia trbv9 del receptor de las celulas t humanas
PE20250740A1 (es) Anticuerpos multiespecificos con especificidad para ror1 y cd3
CL2018003072A1 (es) Anticuerpos anti-basigin humanizados y uso de los mismos.
CR20210091A (es) Receptores químericos de steap1 y métodos de uso de los mismos antecedentes de la invención
AR114110A1 (es) Anticuerpo anti-trka
MX2025010708A (es) Composiciones anti-cd28
MX2022009704A (es) Receptores de antigenos quimericos con mutaciones de cd28 y uso de los mismos.
CO2025007355A2 (es) Anticuerpo anti-trem2 y usos del mismo